Key Drivers
- Margin Compression
- Debt Pressure
- Cash Resilience
AIAI Summary
COLL should be viewed as a leveraged transition story rather than a stable cash generator: JORNAY PM and AZSTARYS are creating real ADHD growth, but the thin margins, weak interest coverage, and heavy debt mean the stock likely stays under pressure unless management proves it can grow, delever, and defend cash flow at the same time.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Margin Compression
- •Debt Pressure
- •Cash Resilience
COLL posted a solid FY2025 on strong margins and cash flow, but the latest quarter saw revenue, margins, and earnings weaken sharply as leverage rose, interest coverage collapsed, and liquidity tightened despite still-positive free cash flow.
Price Behavior
Key Price Behavior Insights:
- •Lower highs
- •Oversold bounce
- •Failed support
COLL remains in a weak downtrend over the last month, but the rebound from $25.70 to $28.23 shows short-term stabilization; $29.10-$29.50 is near-term resistance while $25.70 is key support. ക
Sharp drop into oversold territory followed by a small rebound from $25.70 to $28.23
Sentiment & News
Key News Insights:
- •ADHD Growth
- •AZSTARYS Deal
- •Capital Return
Collegium is showing a successful pivot from legacy pain products to higher-growth ADHD/CNS assets, driven by a Q2 beat, AZSTARYS completion, and strong JORNAY PM momentum.
The news is mildly positive for the stock because it reinforces revenue diversification, cash generation, and a longer-term growth runway
Similar Companies in Healthcare
Other companies in the same sector with AI ratings